Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Dose Escalation Part:
- People with a confirmed diagnosis of acute myeloid leukemia (a type of blood cancer) who are on their second or third round of treatment
- People with a confirmed diagnosis of myelodysplastic syndrome (a bone marrow disorder) that has not responded well to treatment, who are on their second or third round of treatment, and whose condition is considered high risk based on a standard medical scoring system called IPSS-R
- People who are generally well enough to carry out normal daily activities with little to no limitation (as assessed by a standard medical scale)
- People who are able to understand, agree to, and sign a consent form before any study procedures begin
- People who are willing and able to follow all study requirements, including having bone marrow samples taken
Expansion Cohort Part:
- People with a confirmed diagnosis of acute myeloid leukemia who are on their second or third round of treatment
- People who are generally well enough to carry out some daily activities (a slightly broader level of fitness than the dose escalation part, as assessed by a standard medical scale)
- People who are able to understand, agree to, and sign a consent form before any study procedures begin
- People who are willing and able to follow all study requirements, including having bone marrow samples taken
Who may not be able to join:
- People for whom a standard, approved treatment option is currently available
- People for whom a stem cell transplant (a procedure using donor blood stem cells) is considered a suitable option at the time of joining
- People diagnosed with a specific subtype of blood cancer called acute promyelocytic leukemia (also known as M3)
- People whose blood cancer has actively spread to the brain or spinal fluid
- People who have received a stem cell transplant within the 100 days before the study treatment would begin
- Women who are currently breastfeeding or plan to breastfeed during the study
- Women who have a positive pregnancy test
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Norbert Vey, MD, Institut Paoli Calmettes, Marseille, France
Phone: +33(0)147200014
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of dose limiting toxicity (DLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.